ESPERION THERAPEUTICS INC NE's ticker is ESPR and the CUSIP is 29664W105. A total of 168 filers reported holding ESPERION THERAPEUTICS INC NE in Q1 2020. The put-call ratio across all filers is 1.51 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2022 | $115,170 | -7.9% | 18,516 | 0.0% | 0.00% | – |
| Q3 2022 | $125,000 | +5.9% | 18,516 | -1.1% | 0.00% | – |
| Q2 2022 | $118,000 | +14.6% | 18,726 | -14.6% | 0.00% | – |
| Q1 2022 | $103,000 | -59.8% | 21,916 | +140.2% | 0.00% | – |
| Q1 2021 | $256,000 | -26.9% | 9,124 | -31.2% | 0.00% | – |
| Q4 2020 | $350,000 | -0.6% | 13,268 | +41.5% | 0.00% | -100.0% |
| Q3 2020 | $352,000 | -96.7% | 9,374 | -95.5% | 0.00% | -95.2% |
| Q2 2020 | $10,806,000 | +67.3% | 210,610 | +3.9% | 0.02% | +40.0% |
| Q1 2020 | $6,460,000 | -44.2% | 202,631 | +5.1% | 0.02% | -25.0% |
| Q4 2019 | $11,570,000 | +951.8% | 192,711 | +542.4% | 0.02% | +900.0% |
| Q3 2019 | $1,100,000 | -56.8% | 30,000 | -45.2% | 0.00% | -60.0% |
| Q2 2019 | $2,545,000 | -48.6% | 54,702 | -55.6% | 0.01% | -44.4% |
| Q1 2019 | $4,952,000 | -55.3% | 123,334 | -48.7% | 0.01% | -55.0% |
| Q4 2018 | $11,067,000 | – | 240,590 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Boxer Capital, LLC | 1,275,000 | $45,020,000 | 9.84% |
| Aviva Holdings Ltd. | 340,100 | $12,009,000 | 5.60% |
| Aisling Capital LLC | 837,125 | $29,559,000 | 5.38% |
| RA Capital Management | 704,701 | $24,883,000 | 3.05% |
| Rhenman & Partners Asset Management AB | 543,347 | $19,186,000 | 3.04% |
| BB BIOTECH AG | 1,408,542 | $49,736,000 | 1.63% |
| Antipodean Advisors LLC | 91,000 | $3,213,000 | 1.57% |
| Iguana Healthcare Management, LLC | 75,000 | $2,648,000 | 1.31% |
| Crawford Lake Capital Management, LLC | 93,551 | $3,303,000 | 1.31% |
| FT Options LLC | 22,834 | $806,000 | 1.06% |